Q3 EPS Forecast for Jazz Pharmaceuticals Reduced by Analyst

Key Points

• Zacks Research has reduced its Q3 2026 earnings per share estimate for Jazz Pharmaceuticals from $4.73 to $4.72, maintaining a "Hold" rating on the stock.
• Several research firms have increased their price targets for Jazz Pharmaceuticals, with Truist Financial raising it to $205.00 and Goldman Sachs to $185.00, both indicating a "buy" rating.
• Jazz Pharmaceuticals experienced a 2.0% decrease in share price, with its current trading value at $135.43, amidst institutional trading activities that show significant stake increases.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) - Equities research analysts at Zacks Research decreased their Q3 2026 earnings per share estimates for Jazz Pharmaceuticals in a note issued to investors on Thursday, October 9th. Zacks Research analyst Team now expects that the specialty pharmaceutical company will post earnings per share of $4.72 for the quarter, down from their previous estimate of $4.73. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Jazz Pharmaceuticals' current full-year earnings is $16.96 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals' Q1 2027 earnings at $4.20 EPS, Q3 2027 earnings at $5.44 EPS and FY2027 earnings at $20.52 EPS.

A number of other research firms also recently weighed in on JAZZ. Truist Financial raised their price target on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. The Goldman Sachs Group raised their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a research report on Friday, August 29th. Needham & Company LLC restated a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Deutsche Bank Aktiengesellschaft initiated coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target on the stock. Finally, Morgan Stanley raised their price target on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the company an "overweight" rating in a research report on Wednesday, September 24th. Fourteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $178.93.

Jazz Pharmaceuticals Trading Down 2.0%

Shares of JAZZ opened at $135.43 on Monday. The firm's 50 day simple moving average is $125.87 and its 200 day simple moving average is $115.58. The company has a market capitalization of $8.22 billion, a P/E ratio of -20.12, a P/E/G ratio of 8.32 and a beta of 0.28. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. Jazz Pharmaceuticals has a 1-year low of $95.49 and a 1-year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The company had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the prior year, the business earned $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS.

Institutional Trading of Jazz Pharmaceuticals

Large investors have recently modified their holdings of the business. Philip James Wealth Mangement LLC grew its stake in shares of Jazz Pharmaceuticals by 42.0% in the second quarter. Philip James Wealth Mangement LLC now owns 15,797 shares of the specialty pharmaceutical company's stock worth $1,676,000 after purchasing an additional 4,675 shares during the last quarter. State of Alaska Department of Revenue grew its stake in shares of Jazz Pharmaceuticals by 75.1% in the second quarter. State of Alaska Department of Revenue now owns 57,933 shares of the specialty pharmaceutical company's stock worth $6,147,000 after purchasing an additional 24,850 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its stake in shares of Jazz Pharmaceuticals by 38.9% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 4,369 shares of the specialty pharmaceutical company's stock worth $542,000 after purchasing an additional 1,223 shares during the last quarter. Inspire Investing LLC bought a new stake in shares of Jazz Pharmaceuticals in the first quarter worth about $689,000. Finally, Baird Financial Group Inc. bought a new stake in shares of Jazz Pharmaceuticals in the first quarter worth about $539,000. 89.14% of the stock is owned by institutional investors.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total value of $771,720.00. Following the transaction, the director owned 429,973 shares in the company, valued at approximately $55,303,127.26. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 11,500 shares of company stock valued at $1,525,280 in the last quarter. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.